文献速递湿疹皮炎与荨麻疹

巴瑞替尼联合外用糖皮质激素治疗中重度特应性皮炎成人患者的长期疗效(至68周):BREEZE-AD7研究中治疗应答者、部分应答者和无应答者的分析

Long-term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-01-20

基于3期研究BREEZE-AD7及其扩展研究BREEZE-AD3,分析巴瑞替尼联合外用糖皮质激素治疗中重度特应性皮炎成人患者的长期疗效。巴瑞替尼4mg和2mg联合外用糖皮质激素在连续治疗68周内维持了具有临床意义的持续疗效。

要点

  • 巴瑞替尼4mg联合外用糖皮质激素在68周内维持vIGA-AD(0,1)应答率21.6%–26.5%。
  • 巴瑞替尼4mg联合外用糖皮质激素的EASI75应答率在32–68周为40.2%–46.1%。
  • 巴瑞替尼2mg和4mg联合外用糖皮质激素均维持瘙痒NRS≥4分改善。

核心结论

  • 巴瑞替尼4mg和2mg联合外用糖皮质激素在连续治疗68周内维持了具有临床意义的持续疗效。

研究设计与样本

  • 3期研究BREEZE-AD7(NCT03733301)完成后,应答者或部分应答者(vIGA-AD™≤2)以原巴瑞替尼2mg或4mg联合外用糖皮质激素剂量进入扩展研究BREEZE-AD3(NCT03334435)。
  • 无应答者(vIGA-AD 3,4)中接受巴瑞替尼2mg者按1:1重新随机分配至巴瑞替尼2mg或4mg,接受巴瑞替尼4mg者维持原剂量。
  • 分析巴瑞替尼4mg意向性治疗(ITT)队列(N=102)、巴瑞替尼4mg应答者或部分应答者队列(N=63)和巴瑞替尼2mg应答者或部分应答者队列(N=53)。
  • 缺失数据采用末次观测值结转法填补。

主要发现

  • 巴瑞替尼4mg ITT队列(N=102)第32周、第52周和第68周达到vIGA-AD(0,1)的比例分别为21.6%、26.5%和23.5%;EASI75分别为46.1%、40.2%和43.1%;瘙痒NRS≥4分改善在第16周为47.3%,第32周为40.6%。
  • 巴瑞替尼4mg应答者或部分应答者队列(N=63)第32周、第52周和第68周达到vIGA-AD(0,1)的比例分别为31.7%、33.3%和34.9%;EASI75分别为57.1%、49.2%和49.2%;瘙痒NRS≥4分改善在第16周为53.6%,第32周为46.4%。
  • 巴瑞替尼2mg应答者或部分应答者队列(N=53)第32周、第52周和第68周达到vIGA-AD(0,1)的比例分别为39.6%、45.3%和30.2%;EASI75分别为77.4%、69.8%和58.5%;瘙痒NRS≥4分改善在第16周为56.3%,第32周为47.9%。
  • 主要终点为第16周、第36周和第52周(即连续治疗第32周、第52周和第68周)达到vIGA-AD(0,1)的患者比例。

关键数值与推荐

  • 巴瑞替尼4mg ITT队列第32周、第52周和第68周vIGA-AD(0,1)应答率分别为21.6%、26.5%和23.5%。
  • 巴瑞替尼4mg应答者或部分应答者队列第32周、第52周和第68周vIGA-AD(0,1)应答率分别为31.7%、33.3%和34.9%。
  • 巴瑞替尼2mg应答者或部分应答者队列第32周、第52周和第68周vIGA-AD(0,1)应答率分别为39.6%、45.3%和30.2%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Baricitinib demonstrated efficacy in treating adults with moderate-to-severe atopic dermatitis (AD) in Phase 3 clinical trials. OBJECTIVE: To examine long-term efficacy of baricitinib combined with topical corticosteroids (TCS) in adult patients from a Phase 3 study, BREEZE-AD7 (NCT03733301), enrolled in ongoing extension study, BREEZE-AD3 (NCT03334435). METHODS: Upon BREEZE-AD7 completion, responders or partial responders (RPR [vIGA-AD™ ≤2]) receiving baricitinib 2-mg or 4-mg + TCS maintained their original treatment doses in BREEZE-AD3. Nonresponders (NR; vIGA-AD 3,4) receiving baricitinib 2-mg were rerandomized 1:1 to baricitinib 2-mg or 4-mg; NR receiving baricitinib 4-mg remained on same dose. Integrated data from all patients (RPR + NR = baricitinib 4-mg intent-to-treat [ITT] cohort) receiving continuous baricitinib 4-mg in BREEZE-AD7 through BREEZE-AD3 were analysed, along with baricitinib 4-mg or 2-mg RPR cohorts. Primary endpoint was proportion of patients with vIGA-AD (0,1) at Weeks 16, 36 and 52 (Weeks 32, 52 and 68 of continuous therapy). Additional outcomes included improvement in EASI75 and Itch NRS (up to Week 32). Missing data were imputed by last observation carried forward. RESULTS: In baricitinib 4-mg ITT cohort (N = 102), proportions of patients achieving vIGA-AD (0,1) at Week 32, Week 52, and Week 68 were 21.6%, 26.5% and 23.5%; EASI75 were 46.1%, 40.2% and 43.1%, respectively. Itch NRS ≥4-point improvement (Itch ≥4) were 47.3% at Week 16 and 40.6% at Week 32. In baricitinib 4-mg RPR cohort (N = 63), proportions of patients achieving vIGA-AD (0,1) at Week 32, Week 52 and Week 68 were 31.7%, 33.3% 34.9%, respectively; EASI75 were 57.1%, 49.2% and 49.2%, respectively. Itch ≥4 were 53.6% at Week 16 and 46.4% at Week 32. Corresponding proportions for baricitinib 2-mg RPR cohort (N = 53) for vIGA-AD (0,1) were 39.6%, 45.3% and 30.2%; EASI75 were 77.4%, 69.8% and 58.5%, respectively. Itch ≥4 were 56.3% at Week 16 and 47.9% at Week 32. CONCLUSION: Baricitinib 4-mg and 2-mg combined with TCS maintained clinically meaningful sustained efficacy over 68 weeks of continuous treatment.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Silverberg JI, Simpson EL, Thyssen JP, et al. Long-term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7. J Eur Acad Dermatol Venereol. 2023. PMID: 36514996. doi:10.1111/jdv.18816

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。